Loading...
 
Mediterr J Rheumatol 2019;30(Supp 1):63-8
The role of the Nocebo effect in the use of biosimilars in routine rheumatology clinical practice
Authors Information
1First Department of Propaedeutic Internal Medicine, Joint Rheumatology Program, National & Kapodistrian University
of Athens Medical School, Athens, Greece
2Clinical Research Unit, Dudley Group NHS Foundation Trust, Dudley, UK,
3Arthritis Research UK Centre for Epidemiology, University of Manchester, Manchester, UK
References
  1. Boone NW, Liu L, Romberg-Camps MJ, Duijsens L, Houwen C, van der Kuy PHM, et al. The nocebo effect challenges the non-medical infliximab switch in practice. Eur J Clin Pharmacol 2018;74(5):655-61. [https://doi.org/10.1007/s00228-018-2418-4] [PMID: 29368188] [PMCID: PMC5893662]
  2. Hermans L, Nijs J, Calders P, De Clerck L, Moorkens G, Hans G, et al. Influence of Morphine and Naloxone on Pain Modulation in Rheumatoid Arthritis, Chronic Fatigue Syndrome/Fibromyalgia, and Controls: A Double-Blind, Randomized, Placebo-Controlled, Cross-Over Study. Pain Pract 2018;18(4):418-30. [https://doi.org/10.1111/papr.12613] [PMID: 28722815]
  3. Nestoriuc Y, Orav EJ, Liang MH, Horne R, Barsky AJ. Prediction of nonspecific side effects in rheumatoid arthritis patients by beliefs about medicines. Arthritis Care Res (Hoboken) 2010;62(6):791-9. [https://doi.org/10.1002/acr.20160] [PMID: 20191574] [PMCID: PMC2940323]
  4. Tweehuysen L, van den Bemt BJF, van Ingen IL, de Jong AJL, van der Laan WH, van den Hoogen FHJ, et al. Subjective Complaints as the Main Reason for Biosimilar Discontinuation After Open-Label Transition From Reference Infliximab to Biosimilar Infliximab. Arthritis Rheumatol 2018; 70(1):60-8. [https://doi.org/10.1002/art.40324] [PMID: 29045077]
  5. Kravvariti E, Kitas GD, Mitsikostas DD, Sfikakis PP. Nocebos in rheumatology: emerging concepts and their implications for clinical practice. Nat Rev Rheumatol 2018; 4(12):727-40. [https://doi.org/10.1038/s41584-018-0110-9] [PMID: 30361674]
  6. Schedlowski M, Enck P, Rief W, Bingel U. Neuro-Bio-Behavioral Mechanisms of Placebo and Nocebo Responses: Implications for Clinical Trials and Clinical Practice. Pharmacol Rev 2015;67(3):697-730. [https://doi.org/10.1124/pr.114.009423] [PMID: 26126649]
  7. Apkarian AV, Bushnell MC, Treede RD, Zubieta JK. Human brain mechanisms of pain perception and regulation in health and disease. Eur J Pain 2005;9(4):463-84. [https://doi.org/10.1016/j.ejpain.2004.11.001] [PMID: 15979027]
  8. Benedetti F, Lanotte M, Lopiano L, Colloca L. When words are painful: unraveling the mechanisms of the nocebo effect. Neuroscience 2007;147(2):260-71. [https://doi.org/10.1016/j.neuroscience.2007.02.020] [PMID: 17379417]
  9. Jensen KB, Kaptchuk TJ, Chen X, Kirsch I, Ingvar M, Gollub RL, et al. A Neural Mechanism for Nonconscious Activation of Conditioned Placebo and Nocebo Responses. Cereb Cortex 2015;25(10):3903-10. [https://doi.org/10.1093/cercor/bhu275] [PMID: 25452576] [PMCID: PMC4585522]
  10. Palermo S, Benedetti F, Costa T, Amanzio M. Pain anticipation: an activation likelihood estimation meta-analysis of brain imaging studies. Hum Brain Mapp 2015;36(5):1648-61. [https://doi.org/10.1002/hbm.22727] [PMID: 25529840]
  11. Tracey I. Getting the pain you expect: mechanisms of placebo, nocebo and reappraisal effects in humans. Nat Me 2010;16(11):1277-83. [https://doi.org/10.1038/nm.2229] [PMID: 20948533]
  12. LaBar KS, Gatenby JC, Gore JC, LeDoux JE, Phelps EA. Human amygdala activation during conditioned fear acquisition and extinction: a mixed-trial fMRI study. Neuron 1998;20(5):937-45. [PMID: 9620698]
  13. Colloca L, Benedetti F. Nocebo hyperalgesia: how anxiety is turned into pain. Curr Opin Anaesthesiol 2007;20(5):435-9. [https://doi.org/10.1097/ACO.0b013e3282b972fb] [PMID: 17873596]
  14. Vambheim SM, Flaten MA. A systematic review of sex differences in the placebo and the nocebo effect. J Pain Res 2017;10:1831-9. [https://doi.org/10.2147/JPR.S134745] [PMID: 28831271] [PMCID: PMC5548268]
  15. Amanzio M, Palermo S, Skyt I, Vase L. Lessons Learned From Nocebo Effects in Clinical Trials for Pain Conditions and Neurodegenerative Disorders. J Clin Psychopharmacol 2016;36(5):475-82. [https://doi.org/10.1097/JCP.0000000000000556] [PMID: 27580494]
  16. Barsky AJ, Orav EJ, Ahern DK, Rogers MP, Gruen SD, Liang MH. Somatic style and symptom reporting in rheumatoid arthritis. Psychosomatics 1999;40(5):396-403. [PMID: 10479944]
  17. Colloca L, Lopiano L, Lanotte M, Benedetti F. Overt versus covert treatment for pain, anxiety, and Parkinson's disease. Lancet Neurol 2004;3(11):679-84. [https://doi.org/10.1016/S1474-4422(04)00908-1] [PMID: 15488461]
  18. Klinger R, Blasini M, Schmitz J, Colloca L. Nocebo effects in clinical studies: hints for pain therapy. Pain Rep 2017;2(2). [https://doi.org/10.1097/PR9.0000000000000586] [PMID: 29034363] [PMCID: PMC5639717]
  19. Amanzio M, Corazzini LL, Vase L, Benedetti F. A systematic review of adverse events in placebo groups of anti-migraine clinical trials. Pain 2009;146(3):261-9. [https://doi.org/10.1016/j.pain.2009.07.010] [PMID: 19781854]
  20. Colloca L, Finniss D. Nocebo effects, patient-clinician communication, and therapeutic outcomes. JAMA 2012;307(6):567-8. [https://doi.org/10.1001/jama.2012.115] [PMID: 22318275]
  21. van Laarhoven AI, Vogelaar ML, Wilder-Smith OH, van Riel PL, van de Kerkhof PC, Kraaimaat FW, et al. Induction of nocebo and placebo effects on itch and pain by verbal suggestions. Pain 2011;152(7):1486-94. [https://doi.org/10.1016/j.pain.2011.01.043] [PMID: 21353388]
  22. Zhang A, Lee YC. Mechanisms for Joint Pain in Rheumatoid Arthritis (RA): from Cytokines to Central Sensitization. Curr Osteoporos Rep 2018;16(5):603-10. [https://doi.org/10.1007/s11914-018-0473-5] [PMID: 30128836] [PMCID: PMC6157001]
  23. Potvin S, Marchand S. Pain facilitation and pain inhibition during conditioned pain modulation in fibromyalgia and in healthy controls. Pain 2016;157(8):1704-10. [https://doi.org/10.1097/j.pain.0000000000000573] [PMID: 27045524]
  24. Gwilym SE, Keltner JR, Warnaby CE, Carr AJ, Chizh B, Chessell I, et al. Psychophysical and functional imaging evidence supporting the presence of central sensitization in a cohort of osteoarthritis patients. Arthritis Rheum 2009;61(9):1226-34. [https://doi.org/10.1002/art.24837] [PMID: 19714588]
  25. Mitsikostas DD, Chalarakis NG, Mantonakis LI, Delicha EM, Sfikakis PP. Nocebo in fibromyalgia: meta-analysis of placebo-controlled clinical trials and implications for practice. Eur J Neurol 2012;19(5):672-80. [https://doi.org/10.1111/j.1468-1331.2011.03528.x] [PMID: 21973313]
  26. Cepeda MS, Lobanov V, Berlin JA. Use of ClinicalTrials.gov to estimate condition-specific nocebo effects and other factors affecting outcomes of analgesic trials. J Pain 2013;14(4):405-11. [https://doi.org/10.1016/j.jpain.2012.12.011] [PMID: 23453563]
  27. Odinet JS, Day CE, Cruz JL, Heindel GA. The Biosimilar Nocebo Effect? A Systematic Review of Double-Blinded Versus Open-Label Studies. J Manag Care Spec Pharm 2018;24(10):952-9. [https://doi.org/10.18553/jmcp.2018.24.10.952] [PMID: 30247100]
  28. Jorgensen KK, Olsen IC, Goll GL, Lorentzen M, Bolstad N, Haavardsholm EA, et al. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial. Lancet 2017;389(10086):2304-16. [https://doi.org/10.1016/S0140-6736(17)30068-5] [PMID: 28502609]
  29. Park W, Suh CH, Shim SC, Molina FFC, Jeka S, Medina-Rodriguez FG, et al. Efficacy and Safety of Switching from Innovator Rituximab to Biosimilar CT-P10 Compared with Continued Treatment with CT-P10: Results of a 56-Week Open-Label Study in Patients with Rheumatoid Arthritis. BioDrugs 2017;31(4):369-77. [https://doi.org/10.1007/s40259-017-0233-6] [PMID: 28600696] [PMCID: PMC5548826]
  30. Weinblatt ME, Baranauskaite A, Dokoupilova E, Zielinska A, Jaworski J, Racewicz A, et al. Switching From Reference Adalimumab to SB5 (Adalimumab Biosimilar) in Patients With Rheumatoid Arthritis: Fifty-Two-Week Phase III Randomized Study Results. Arthritis Rheumatol 2018;70(6):832-40. [https://doi.org/10.1002/art.40444] [PMID: 29439289] [PMCID: PMC6001519]
  31. Yoo DH, Prodanovic N, Jaworski J, Miranda P, Ramiterre E, Lanzon A, et al. Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study. Ann Rheum Dis 2017;76(2):355-63. [https://doi.org/10.1136/annrheumdis-2015-208786] [PMID: 27130908] [PMCID: PMC5284338]
  32. Cohen S, Genovese MC, Choy E, Perez-Ruiz F, Matsumoto A, Pavelka K, et al. Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: a randomised, double-blind, phase III equivalence study. Ann Rheum Dis 2017;76(10):1679-87. [https://doi.org/10.1136/annrheumdis-2016-210459] [PMID: 28584187] [PMCID: PMC5629940]
  33. Smolen JS, Choe JY, Prodanovic N, , Niebrzydowski J, Staykov I, Dokoupilova E, et al. Safety, immunogenicity and efficacy after switching from reference infliximab to biosimilar SB2 compared with continuing reference infliximab and SB2 in patients with rheumatoid arthritis: results of a randomised, double-blind, phase III transition study. Ann Rheum Dis 2018;77(2):234-40. [https://doi.org/10.1136/annrheumdis-2017-211741] [PMID: 29042358] [PMCID: PMC5867419]
  34. Abdalla A, Byrne N, Conway R, Walsh T, Mannion G, Hanly M, et al. Long-term safety and efficacy of biosimilar infliximab among patients with inflammatory arthritis switched from reference product. Open Access Rheumatol 2017;9:29-35. [https://doi.org/10.2147/OARRR.S124975] [PMID: 28331376] [PMCID: PMC5349501]
  35. Avouac J, Molto A, Abitbol V, Etcheto A, Salcion A, Gutermann L, et al. Systematic switch from innovator infliximab to biosimilar infliximab in inflammatory chronic diseases in daily clinical practice: The experience of Cochin University Hospital, Paris, France. Semin Arthritis Rheum 2018;47(5):741-8. [https://doi.org/10.1016/j.semarthrit.2017.10.002] [PMID: 29102156]
  36. Benucci M, Gobbi FL, Bandinelli F, Damiani A, Infantino M, Grossi V, et al. Safety, efficacy and immunogenicity of switching from innovator to biosimilar infliximab in patients with spondyloarthritis: a 6-month real-life observational study. Immunol Res 2017;65(1):419-22. [https://doi.org/10.1007/s12026-016-8843-5] [PMID: 27449503]
  37. Glintborg B, Sorensen IJ, Loft AG, Lindegaard H, Linauskas A, Hendricks O, et al. A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry. Ann Rheum Dis 2017;76(8):1426-31. [https://doi.org/10.1136/annrheumdis-2016-210742] [PMID: 28473425]
  38. Holroyd CR, Parker L, Bennett S, Zarroug J, Underhill C, Davidson B, et al. Switching to biosimilar infliximab: real world data in patients with severe inflammatory arthritis. Clin Exp Rheumatol 2018;36(1):171-2. [PMID: 29352847]
  39. Nikiphorou E, Kautiainen H, Hannonen P, Asikainen J, Kokko A, Rannio T, et al. Clinical effectiveness of CT-P13 (Infliximab biosimilar) used as a switch from Remicade (infliximab) in patients with established rheumatic disease. Report of clinical experience based on prospective observational data. Expert Opin Biol Ther 2015;15(12):1677-83. [https://doi.org/10.1517/14712598.2015.1103733] [PMID: 26549204]
  40. Scherlinger M, Germain V, Labadie C, Barnetche T, Truchetet ME, Bannwarth B, et al. Switching from originator infliximab to biosimilar CT-P13 in real-life: The weight of patient acceptance. Joint Bone Spine 2018;85(5):561-7. [https://doi.org/10.1016/j.jbspin.2017.10.003] [PMID: 29154920]
  41. Bakalos G, Zintzaras E. Drug Discontinuation in Studies Including a Switch From an Originator to a Biosimilar Monoclonal Antibody: A Systematic Literature Review. Clin Ther 2019;41(1):155-73 e13. [https://doi.org/10.1016/j.clinthera.2018.11.002] [PMID: 30551802]
  42. Chavarria V, Vian J, Pereira C, Data-Franco J, Fernandes BS, Berk M, et al. The Placebo and Nocebo Phenomena: Their Clinical Management and Impact on Treatment Outcomes. Clin Ther 2017;39(3):477-86. [https://doi.org/10.1016/j.clinthera.2017.01.031] [PMID: 28237673]
  43. Gupta A, Thompson D, Whitehouse A, Collier T, Dahlof B, Poulter N, et al. Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phase. Lancet 2017;389(10088):2473-81. [https://doi.org/10.1016/S0140-6736(17)31075-9] [PMID: 28476288]
  44. Cohen H, Beydoun D, Chien D, Lessor T, McCabe D, Muenzberg M, et al. Awareness, Knowledge, and Perceptions of Biosimilars Among Specialty Physicians. Adv Ther 2017;33(12):2160-72. [https://doi.org/10.1007/s12325-016-0431-5] [PMID: 27798772] [PMCID: PMC5126187]
  45. Peyrin-Biroulet L, Lonnfors S, Roblin X, Danese S, Avedano L. Patient Perspectives on Biosimilars: A Survey by the European Federation of Crohn's and Ulcerative Colitis Associations. J Crohns Colitis 2017;11(1):128-33. [https://doi.org/10.1093/ecco-jcc/jjw138] [PMID: 27481878]
  46. Frantzen L, Cohen JD, Trope S, et al. Patients' information and perspectives on biosimilars in rheumatology: a French nation-wide survey. Joint Bone Spine 2019. [http://doi.org/10.1016/j.jbspin.2019.01.001]
  47. Cepeda MS, Lobanov V, Berlin JA. Using Sherlock and ClinicalTrials.gov data to understand nocebo effects and adverse event dropout rates in the placebo arm. J Pain;14(9):999. [https://doi.org/10.1016/j.jpain.2013.06.005] [PMID: 23993418]
  48. Desai RJ, Sarpatwari A, Dejene S, Khan NF, Lii J, Rogers JR, et al. Differences in rates of switchbacks after switching from branded to authorized generic and branded to generic drug products: cohort study. BMJ 2018;361:k1180. [https://doi.org/10.1136/bmj.k1180] [PMID: 29615391] [PMCID: PMC5881140]
  49. Mitsikostas DD. Nocebo in headaches: implications for clinical practice and trial design. Curr Neurol Neurosci Rep 2012;12(2):132-7. [https://doi.org/10.1007/s11910-011-0245-4] [PMID: 22193945]
  50. Tweehuysen L, Huiskes VJ, van den Bemt BJ, Vriezekolk JE, Teerenstra S, van den Hoogen FHJ, et al. Open-Label Non-Mandatory Transitioning From Originator Etanercept to Biosimilar SB4: 6-Month Results From a Controlled Cohort Study. Arthritis Rheumatol 2018;70(9):1408-18. [https://doi.org/10.1002/art.40516] [PMID: 29609207]
  51. Mitsikostas DD, Deligianni CI. Q-No: a questionnaire to predict nocebo in outpatients seeking neurological consultation. Neurol Sci 2015;36(3):379-81. [https://doi.org/10.1007/s10072-014-1959-2] [PMID: 25249398]
  52. Younger J, Gandhi V, Hubbard E, Mackey S. Development of the Stanford Expectations of Treatment Scale (SETS): a tool for measuring patient outcome expectancy in clinical trials. Clin Trials 2012;9(6):767-76. [https://doi.org/10.1177/1740774512465064] [PMID: 23169874]
  53. Neame R, Hammond A. Beliefs about medications: a questionnaire survey of people with rheumatoid arthritis. Rheumatology (Oxford) 2005;44(6):762-7. [https://doi.org/10.1093/rheumatology/keh587] [PMID: 15741193]
  54. Bartels DJP, van Laarhoven AIM, Stroo M, Hijne K, Peerdeman KJ, Donders ART, et al. Minimizing nocebo effects by conditioning with verbal suggestion: A randomized clinical trial in healthy humans. PLoS One 2017; 12(9): e0182959. [https://doi.org/10.1371/journal.pone.0182959] [PMID: 28910291] [PMCID: PMC5598922]
  55. Webster RK, Weinman J, Rubin GJ. Positively Framed Risk Information in Patient Information Leaflets Reduces Side Effect Reporting: A Double-Blind Randomized Controlled Trial. Ann Behav Med 2018;52(11):920-9. [https://doi.org/10.1093/abm/kax064] [PMID: 30346496]
  56. Colgan S, Faasse K, Martin LR, Stephens MH, Grey A, Petrie KJ. Perceptions of generic medication in the general population, doctors and pharmacists: a systematic review. BMJ Open 2015;5(12):e008915. [https://doi.org/10.1136/bmjopen-2015-008915] [PMID: 26671954] [PMCID: PMC4679988]
  57. Ringe JD, Moller G. Differences in persistence, safety and efficacy of generic and original branded once weekly bisphosphonates in patients with postmenopausal osteoporosis: 1-year results of a retrospective patient chart review analysis. Rheumatol Int 2009;30(2):213-21. [https://doi.org/10.1007/s00296-009-0940-5] [PMID: 19430791]
  58. Tinnermann A, Geuter S, Sprenger C, Finsterbusch J, Buchel C. Interactions between brain and spinal cord mediate value effects in nocebo hyperalgesia. Science 2017;358(6359):105-8. [https://doi.org/10.1126/science.aan1221] [PMID: 28983051]